Pantoprazole

CHEMBL1502 Phase 4 Onaylandı Small molecule

Half-Life

1 hour

Bioavailability

—

Protein Binding

—

Molecular Weight

383.4 g/mol

LogP

2.4

Phase

4

This proton pump inhibitor reduces stomach acid production to treat acid reflux, ulcers, and esophageal damage.

Moleküler Ağırlık

383,3710 g/mol

LogP

2,40

TPSA

106,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Pancreatic Cancer Pain Management Non-Small Cell Lung Cancer Migraine Schizophrenia Oncology Gastroesophageal Reflux Disease Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Obesity Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Chronic Pain Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

İlaç Sınıfları

A — A - Alimentary Tract and Metabolism

Etki Mekanizması

Proton pump inhibitor.

Pharmacokinetics (PK)

Half-Life 1 hour

Pharmacodynamics (PD)

Mekanizma

Proton pump inhibitor.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

COc1ccnc(C[S+]([O-])c2nc3cc(OC(F)F)ccc3[nH]2)c1OC

InChI

InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)

Molecular Formula

C16H15F2N3O4S

HBD / HBA

1 / 9

Döndürülebilir Bağlar

7

Ağır Atomlar

26

ATP4A (Proton Pump (H+/K+-ATPase)) Inhibitor

Primary Target

Minor Pantoprazole + Clopidogrel

Pantoprazole has minimal CYP2C19 inhibitory activity compared with omeprazole, making it the preferred PPI choice in patients on clopidogrel.

Moderate Pantoprazole + Levothyroxine

Like all PPIs, pantoprazole reduces gastric acid and impairs levothyroxine tablet dissolution, leading to decreased T4 absorption and potentially under-treated hypothyroidism.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

This proton pump inhibitor reduces stomach acid production to treat acid reflux, ulcers, and esophageal damage.

Proton pump inhibitor.

Key pharmacokinetic parameters for Pantoprazole: Half-life: 1 hour.

Yes, Pantoprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Metformin Small molecule Omeprazole Small molecule Lansoprazole Small molecule Insulin Glargine Protein

Same Target

Omeprazole Small molecule Lansoprazole Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1502. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4679. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Pantoprazole PillFYI'da

Yapı

Hızlı Veriler

Class: A - Alimentary Tract and Metabolism
Formül: C16H15F2N3O4S
Eş Anlamlılar: 5

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Pantoprazole

Terapötik Alanlar

İlaç Sınıfları

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No side effects recorded

Sıkça Sorulan Sorular

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget